CoChat

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.

Abstract

4-1BB (CD137, tumor necrosis factor receptor superfamily 9) is an inducible costimulatory receptor expressed on activated T and natural killer (NK) cells. 4-1BB ligation on T cells triggers a signaling cascade that results in upregulation of antiapoptotic molecules, cytokine secretion, and enhanced effector function. In dysfunctional T cells that have a decreased cytotoxic capacity, 4-1BB ligation demonstrates a potent ability to restore effector functions. On NK cells, 4-1BB signaling can increase antibody-dependent cell-mediated cytotoxicity. Agonistic monoclonal antibodies targeting 4-1BB have been developed to harness 4-1BB signaling for cancer immunotherapy. Preclinical results in a variety of induced and spontaneous tumor models suggest that targeting 4-1BB with agonist antibodies can lead to tumor clearance and durable antitumor immunity. Clinical trials of 2 agonist antibodies, urelumab and utomilumab, are ongoing. Despite initial signs of efficacy, clinical development of urelumab has been hampered by inflammatory liver toxicity at doses >1 mg/kg. Utomilumab has a superior safety profile, but is a less potent 4-1BB agonist relative to urelumab. Both antibodies have demonstrated promising results in patients with lymphoma and are being tested in combination therapy trials with other immunomodulatory agents. In an effort to optimally leverage 4-1BB-mediated immune activation, the next generation of 4-1BB targeting strategies attempts to decouple the observed antitumor efficacy from the on-target liver toxicity. Multiple therapeutics that attempt to restrict 4-1BB agonism to the tumor microenvironment and minimize systemic exposure have emerged. 4-1BB is a compelling target for cancer immunotherapy and future agents show great promise for achieving potent immune activation while avoiding limiting immune-related adverse events.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2017-06-741041

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

3 retracted

Show all 93 references

Research works printed but not linked: 1

  1. Shuford, 1997, 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses, J Exp Med, 186, 47, 10.1084/jem.186.1.47 · DOI · Paper page

Cited by

See all 499

Metadata

Authors
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I.
Affiliations
  • Stanford Medicine (US)
  • Yale University (US)
  • Centro de Investigación Biomédica en Red (ES)
Venue
Blood
Published
2018-01-04
Volume
131
Issue
1
Pages
49-57
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2767731416
Cited by
499
References
94
Citations by year
2026: 37 · 2025: 40 · 2024: 72 · 2023: 65 · 2022: 62 · 2021: 68 · 2020: 65 · 2019: 60 · 2018: 30
FWCI
4.45
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
4-1BB, agonistic monoclonal antibody, urelumab, utomilumab, T cell activation, natural killer cells, antibody-dependent cellular cytotoxicity, hepatotoxicity, lymphoma, tumor microenvironment, combination immunotherapy, cancer immunotherapy
MeSH terms
Animals, Antibodies, Monoclonal, Humans, Immunotherapy, Neoplasms, Tumor Necrosis Factor Receptor Superfamily, Member 9

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. https://app.cochat.ai/papers/10.1182/blood-2017-06-741041
The paper
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018). Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. https://doi.org/10.1182/blood-2017-06-741041

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.